🎙️Don’t miss this great overview of Head and Neck cancer with the superb @clairepaterson.bsky.social
🎙️this would be great for patients and anyone involved with Head & Neck cancer
www.buzzsprout.com/2342317/epis...
🎙️We speak to the superb @clairepaterson.bsky.social about radiotherapy and new treatments in H&N cancers.
🎙️A great resource for any patient undergoing H&N treatment
@simplyoncology.bsky.social
🎙️We speak to the superb @clairepaterson.bsky.social about radiotherapy and new treatments in H&N cancers.
🎙️A great resource for any patient undergoing H&N treatment
@simplyoncology.bsky.social
At: www.redjournal.org/audio-do/red...
Pro tip: right click on the play bar and download the audio file for better listening
OMET trial: www.redjournal.org/article/S036...
Fabulous editorial: www.redjournal.org/article/S036...
At: www.redjournal.org/audio-do/red...
Pro tip: right click on the play bar and download the audio file for better listening
OMET trial: www.redjournal.org/article/S036...
Fabulous editorial: www.redjournal.org/article/S036...
pubmed.ncbi.nlm.nih.gov/39800346/
pubmed.ncbi.nlm.nih.gov/39800346/
Same survival chemo-SABR 42.3 months vs SABR-alone 41.1 months in #hncsm patients with oligomets
GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using SABR-alone or chemotherapy-SABR
👉 www.redjournal.org/article/S036...
Same survival chemo-SABR 42.3 months vs SABR-alone 41.1 months in #hncsm patients with oligomets
GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using SABR-alone or chemotherapy-SABR
👉 www.redjournal.org/article/S036...
(don't do rocketships on bsky)
#IJROBP
(don't do rocketships on bsky)
#IJROBP